These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 36364143)

  • 1. Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2.
    Guo L; Zafar F; Moeen N; Alshabrmi FM; Lin J; Ali SS; Munir M; Khan A; Wei D
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational screening of natural products to identify potential inhibitors for human neuropilin-1 (NRP1) receptor to abrogate the binding of SARS-CoV-2 and host cell.
    Karkashan A; Attar R
    J Biomol Struct Dyn; 2023 Nov; 41(19):9987-9996. PubMed ID: 36437796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic Potential of Natural Products to Target the SARS-CoV-2 PLpro Using Molecular Screening and Simulation Approaches.
    Sayaf AM; Ahmad H; Aslam MA; Ghani SA; Bano S; Yousafi Q; Suleman M; Khan A; Yeoh KK; Wei DQ
    Appl Biochem Biotechnol; 2023 Nov; 195(11):6959-6978. PubMed ID: 36961512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural communication fingerprinting and dynamic investigation of RBD-hACE2 complex from BA.1 × AY.4 recombinant variant (Deltacron) of SARS-CoV-2 to decipher the structural basis for enhanced transmission.
    Wang J; Fatima Muhammad S; Aman S; Khan A; Munir S; Khan M; Mohammad A; Waheed Y; Munir M; Guo L; Chen L; Wei DQ
    J Biomol Struct Dyn; 2023; 41(16):7665-7676. PubMed ID: 36129018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetracycline as an inhibitor to the SARS-CoV-2.
    Zhao TY; Patankar NA
    J Cell Biochem; 2021 Jul; 122(7):752-759. PubMed ID: 33619758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The XBB.1.5 slightly increase the binding affinity for host receptor ACE2 and exhibit strongest immune escaping features: molecular modeling and free energy calculation.
    Suleman M; Murtaza A; ; Khan H; Rashid F; Alshammari A; Ali L; Khan A; Wei DQ
    Front Mol Biosci; 2023; 10():1153046. PubMed ID: 37325478
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach.
    Mathew SM; Benslimane F; Althani AA; Yassine HM
    Qatar Med J; 2021; 2021(1):12. PubMed ID: 34604010
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity.
    Hanifa M; Salman M; Fatima M; Mukhtar N; Almajhdi FN; Zaman N; Suleman M; Ali SS; Waheed Y; Khan A
    Front Cell Dev Biol; 2022; 10():940863. PubMed ID: 36733340
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition potential of natural flavonoids against selected omicron (B.1.19) mutations in the spike receptor binding domain of SARS-CoV-2: a molecular modeling approach.
    Kumar A; Dutt M; Dehury B; Sganzerla Martinez G; Swan CL; Kelvin AA; Richardson CD; Kelvin DJ
    J Biomol Struct Dyn; 2023 Dec; ():1-15. PubMed ID: 38115191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the medicinal potential of Dark Chemical Matters (DCM) to design promising inhibitors for PLpro of SARS-CoV-2 using molecular screening and simulation approaches.
    Khan A; Liaqat A; Masood A; Ali SS; Ali L; Alshammari A; Alasmari AF; Mohammad A; Waheed Y; Wei DQ
    Saudi Pharm J; 2023 Oct; 31(10):101775. PubMed ID: 37719892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of SARS-CoV-2 ORF6-KPNA2 binding interface and identification of potent small molecule inhibitors to recuse the host immune system.
    Suleman M; Said A; Khan H; Rehman SU; Alshammari A; Crovella S; Yassine HM
    Front Immunol; 2023; 14():1266776. PubMed ID: 38283360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico screening of some compounds derived from the desert medicinal plant Rhazya stricta for the potential treatment of COVID-19.
    Baeshen NA; Albeshri AO; Baeshen NN; Attar R; Karkashan A; Abbas B; Bouback TA; Aljaddawi AA; Refai MY; Abdelkader HS; Al Tamim A; Alowaifeer A; Ahmed F; Baeshen MN
    Sci Rep; 2022 Jul; 12(1):11120. PubMed ID: 35778482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Pandey AK; Verma S
    Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.